Cécile Pascal
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Cécile Pascal has a total of 97 co-authors. Here are the top co-authors by number of shared publications:
Bénédicte Onofri
Sanofi-aventis R&D, Early to Candidate Unit, 1 avenue Pierre Brossolette, 91385 Chilly-Mazarin, France
2 shared publicationsCatherine Monseau
Sanofi-aventis R&D, Early to Candidate Unit, 1 avenue Pierre Brossolette, 91385 Chilly-Mazarin, France
2 shared publicationsChristophe Philippo
Sanofi-aventis R&D, Early to Candidate Unit, 1 avenue Pierre Brossolette, 91385 Chilly-Mazarin, France
2 shared publicationsClaudie Namane
Sanofi-aventis R&D, Early to Candidate Unit, 1 avenue Pierre Brossolette, 91385 Chilly-Mazarin, France
2 shared publicationsEric Nicolaï
Sanofi-aventis R&D, Early to Candidate Unit, 1 avenue Pierre Brossolette, 91385 Chilly-Mazarin, France
2 shared publicationsFrançois Pacquet
Sanofi-aventis R&D, Early to Candidate Unit, 1 avenue Pierre Brossolette, 91385 Chilly-Mazarin, France
2 shared publications
Latest Publications
- 21 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (603)
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance
We report an acylguanidine preclinical candidate with pharmacological features compatible with single low-dose malaria cure.
- 21 July 2021
- Published by American Association for the Advancement of Science (AAAS) in Science Translational Medicine
- Vol. 13 (603)
The antimalarial MMV688533 provides potential for single-dose cures with a high barrier to Plasmodium falciparum parasite resistance
We report an acylguanidine preclinical candidate with pharmacological features compatible with single low-dose malaria cure.
- 1 April 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (7) , 2497-2502
Thiadiazoles as new inhibitors of diacylglycerol acyltransferase type 1
- 1 April 2012
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 22 (7) , 2497-2502
Thiadiazoles as new inhibitors of diacylglycerol acyltransferase type 1
- 1 April 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (8) , 2244-2251
Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11β-hydroxysteroid-dehydrogenase type 1
- 1 April 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (8) , 2244-2251
Pyrrolidine-pyrazole ureas as potent and selective inhibitors of 11β-hydroxysteroid-dehydrogenase type 1
- 1 January 2010
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 2 (1) , 27
081 Analysis of TAZ (tafazzin) and LDB3 (LIM domain-binding3/Cypher/ZASP) genes in Left ventricular non compaction
- 1 January 2010
- Published by Elsevier in Archives of Cardiovascular Diseases Supplements
- Vol. 2 (1) , 27
081 Analysis of TAZ (tafazzin) and LDB3 (LIM domain-binding3/Cypher/ZASP) genes in Left ventricular non compaction